2,825,000 Shares in ProQR Therapeutics (NASDAQ:PRQR) Purchased by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC purchased a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 2,825,000 shares of the biopharmaceutical company's stock, valued at approximately $7,486,000. ProQR Therapeutics comprises approximately 1.0% of Affinity Asset Advisors LLC's holdings, making the stock its 28th biggest position. Affinity Asset Advisors LLC owned approximately 3.46% of ProQR Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Invesco Ltd. bought a new stake in ProQR Therapeutics during the 4th quarter valued at approximately $32,000. ADAR1 Capital Management LLC bought a new stake in shares of ProQR Therapeutics in the fourth quarter valued at about $54,000. Ballentine Partners LLC acquired a new stake in shares of ProQR Therapeutics during the 4th quarter worth approximately $61,000. Jump Financial LLC acquired a new stake in ProQR Therapeutics during the fourth quarter worth $71,000. Finally, Prudential Financial Inc. boosted its position in shares of ProQR Therapeutics by 109.1% during the 4th quarter. Prudential Financial Inc. now owns 27,600 shares of the biopharmaceutical company's stock valued at $73,000 after acquiring an additional 14,400 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Stock Performance

Shares of PRQR stock remained flat at $1.14 during mid-day trading on Friday. The stock had a trading volume of 464,845 shares, compared to its average volume of 585,159. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The stock's 50 day simple moving average is $1.76 and its two-hundred day simple moving average is $2.52. The company has a market cap of $119.94 million, a P/E ratio of -3.56 and a beta of 0.25.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Chardan Capital reiterated a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Friday, March 14th. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price target on the stock in a research note on Monday, March 10th. Oppenheimer started coverage on ProQR Therapeutics in a report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective for the company. Finally, HC Wainwright boosted their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research report on Friday, March 14th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.50.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).